HPO can significantly enhance clinical trials for cancer by providing precise and standardized phenotypic data. This allows for better selection and stratification of patients, ensuring that trial participants have similar phenotypic characteristics. It also facilitates more accurate monitoring of outcomes and side effects, leading to more reliable and reproducible results. Furthermore, HPO can help identify patient subgroups that may benefit from specific interventions, optimizing the design and efficacy of clinical trials.
